Regulatory Stacks

1 published article in Regulatory Stacks

Filter by category
All Regulatory Regulatory Stacks Stacks
Regulatory Stacks Interaction Unknown
After the April 2026 FDA Removal of BPC-157 from the 503A Compounding List, How Should Protocol Designers Rebuild Gut and Pain Stacks?

On April 22, 2026, the FDA removed BPC-157 from Category 2 of the 503A bulk drug substances list, ending its interim compounding authorization. For protocol designers targeting ulcerative colitis or chronic pain, licensed compounding is no longer legally straightforward. Rebuilding requires mapping mechanistic substitutes — primarily KPV, TB-500, and GHK-Cu — against the pathways BPC-157 previously covered.

June 30, 2026 · 9 min read